Bavencio®
(avelumab)

Merck Serono Ltd are the marketing authorisation holder for Bavencio®. This medicine is a Merck-Pfizer co-promote.


What is BAVENCIO and what is it used for?1

Bavencio contains the active substance avelumab, a monoclonal antibody (a type of protein) that attaches to a specific target in the body called PD-L1.

PD-L1 is found on the surface of certain tumour cells, and helps protect them from the immune system (the body’s natural defences). Bavencio binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells.

Bavencio is used in adults to treat:

  • Merkel cell carcinoma (MCC), a rare type of skin cancer, when it is metastatic (has spread to other parts of the body).
  • Urothelial carcinoma (UC), a cancer that originates in the urinary tract, when it is advanced or metastatic (has spread beyond the urinary bladder or to other parts of the body). Bavencio is used as maintenance treatment if the tumour has not grown after so called platinum-based chemotherapy as the first treatment.  
  • Renal cell carcinoma (RCC), a type of kidney cancer, when it is advanced (has spread beyond the kidney or to other parts of the body). For renal cell cancer, Bavencio is to be used in combination with axitinib.

 

REFERENCE INFORMATION

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for BAVENCIO please follow these links:

 

Great Britain
BAVENCIO (avelumab)

Northern Ireland
BAVENCIO (avelumab)

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

 

References

  1. Merck. BAVENCIO® Patient Information Leaflet. January 2021.

 

PP-BAV-GBR-1121 / November 2021